Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13332473 | 0.98 | HPGD (0.53) | HPGDTP53EPHX1ALDH1A1CES2 | |
| SCHEMBL3990546 | 0.98 | HPGD (0.53) | HPGDTP53EPHX1ALDH1A1CES2 | |
| SCHEMBL3993887 | 0.89 | CYP1A2 (0.41) | HPGDTP53EPHX1CES2CES1 | |
| SCHEMBL3986765 | 0.87 | CYP1A2 (0.45) | HPGDTP53EPHX1CES2CES1 | |
| SCHEMBL16270200 | 0.87 | CYP1A2 (0.45) | HPGDTP53EPHX1CES2CES1 | |
| SCHEMBL3988584 | 0.85 | KDM5A (0.49) | HPGDEPHX1MEN1KMT2A | |
| SCHEMBL24042736 | 0.82 | HPGD (0.37) | HPGDTP53EPHX1ALDH1A1CES2 | |
| SCHEMBL27940250 | 0.79 | HPGD (0.54) | HPGDTP53EPHX1ALDH1A1HSD11B1 | |
| SCHEMBL27949317 | 0.79 | HPGD (0.54) | HPGDTP53EPHX1ALDH1A1HSD11B1 | |
| SCHEMBL7714802 | 0.78 | CES2 (0.43) | HPGDEPHX1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021162115-A1 | LAMINATE, DISPLAY DEVICE, AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE | 富士フイルム株式会社 | 2021-08-19 | — | — | WO | disclosed |
| US-20210026199-A1 | COLORANT FILTER, BACKLIGHT UNIT, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20210005673-A1 | COLOR CORRECTION FILTER FOR WHITE ORGANIC ELECTROLUMINESCENT LIGHT SOURCE, AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-01-07 | — | — | US | disclosed |
| US-20200217993-A1 | POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2020-07-09 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | HPGD 1963/4885TP53 2006/4885EPHX1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.